Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05469269 · ClinicalTrials.gov registry record · NA

Cleveland African American Prostate Cancer Project

A NA study of Prostate Cancer, sponsored by Case Comprehensive Cancer Center.

Recruiting
Registry status
NA
Development phase
800
Enrollment target
1
Study location

NCT05469269 is a NA study of Prostate Cancer that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 800 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (32% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05469269, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.

RECRUITING
Registry status
NA
Development phase
800 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to test intervention strategies that encourage and support Black or African American men who are 40 and older to complete prostate cancer screening, and specifically to complete a prostate-specific antigen (PSA) test.

Conditions Studied

Interventions

  • BEHAVIORAL Passive Education
  • BEHAVIORAL Education by Community Navigator
  • BEHAVIORAL Education at Community Outreach Screening Event

Study Locations (1)

Ohio

  • Barbershops Local to Cleveland - Cleveland

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2023-06-09
Est. Completion 2027-09-30
Phase NA

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT05469269

The ClinicalTrials.gov registry entry for NCT05469269 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (32% higher). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Passive Education is the first listed.

NCT05469269 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05469269 about?

NCT05469269 is a clinical study titled "Cleveland African American Prostate Cancer Project". The purpose of this research is to test intervention strategies that encourage and support Black or African American men who are 40 and older to complete prostate cancer screening, and specifically to complete a prostate-specific antigen (PSA) test.

What is the current status of trial NCT05469269?

This trial is currently recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2023-06-09. Estimated completion is 2027-09-30.

What conditions does trial NCT05469269 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT05469269?

The interventions under investigation include: Passive Education (BEHAVIORAL), Education by Community Navigator (BEHAVIORAL), Education at Community Outreach Screening Event (BEHAVIORAL).

Who is sponsoring clinical trial NCT05469269?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05469269 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.